Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 16.16
- Piotroski Score 4.00
- Grade Buy
- Symbol (GKOS)
- Company Glaukos Corporation
- Price $130.28
- Changes Percentage (1.55%)
- Change $1.99
- Day Low $127.41
- Day High $130.29
- Year High $136.61
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/30/2024
- Fiscal Year End N/A
- Average Stock Price Target $120.00
- High Stock Price Target $145.00
- Low Stock Price Target $42.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.88
- Trailing P/E Ratio -39.55
- Forward P/E Ratio -39.55
- P/E Growth -39.55
- Net Income $-134,661,000
Income Statement
Quarterly
Annual
Latest News of GKOS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Here's Why Glaukos (GKOS) Appreciated in Q2
Brown Capital Management's Small Company Fund had a -6.57% return in Q2 2024, underperforming the Russell 2000 Growth index. Glaukos Corporation (NYSE:GKOS) was highlighted as a top pick, with a one-m...
By Yahoo! Finance | 3 weeks ago
